N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced it will be supporting the University of Queensland as part of a recent grant award by the Australian Research Council.
The University of Queensland has announced that Professor Chengzhong Yu, Senior Group Leader, Australian Institute for Bioengineering and Nanotechnology (AIBN) has been awarded a $402,115 grant to develop an improved nanoparticle delivery system that enhances the performance of messenger ribonucleic acid (mRNA) therapies. The new nanoparticle will be based on the Company’s patented nuvec® nanoparticle that it has licensed exclusively from the University of Queensland.
N4 Pharma will work with Professor Yu to tackle the current challenges in manufacturing mRNA therapeutics, by building new knowledge in custom-design of functional nanomaterials for mRNA delivery. mRNA is a highly lucrative field of therapeutic science and is emerging as a major drug platform.
A copy of the full announcement can be found here: https://aibn.uq.edu.au/article/2023/06/linkage-grants-catapult-lab-ideas-production-line
Nigel Theobald, Chief Executive Officer of N4 Pharma, commented:
“We are pleased to continue our close collaboration with Professor Yu and work on new ways to build on the performance of our Nuvec® nanoparticle together.”
